Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

Eli Lilly Could Launch Its Rival To Novo Nordisk's Weight-Loss Drug A Year Earlier Than Expected

An analyst expects Lilly to launch a competitor in weight-loss drugs a year earlier than expected, giving Eli Lilly stock a chance to shine.

Investors Business Daily

The Important — And Overlooked — Caveat Behind Pfizer's Rival To Novo Nordisk In Diabetes

Pfizer hasn't committed to sending a diabetes drug into Phase 3 testing. Instead, the company is waiting on results for another drug,

Investors Business Daily

Pfizer Stock Jumps After Diabetes Drug Tops Ozempic In Weight Loss

An oral drug from Pfizer led to faster weight loss than weekly injections of Novo Nordisk's diabetes drug Ozempic. Pfizer stock jumped.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Friday briefing: Are appetite-suppressing drugs really a fast track to weight loss?

In today’s newsletter: Semaglutide has won endorsements from celebrities and expert drugs advisers and has gone viral on TikTok. But don’t expect a quick fix

The Guardian - UK

Families scramble to find growth hormone drug as shortage drags on

Children who need growth hormone to achieve their full stature are having trouble getting the medicine. A shortage has stretched months longer than expected and could last the rest of the year.

WEKU

WHO issues warning on weight loss drugs

Balanced diet and exercise remain key to losing weight, health body says

The Independent UK

Exclusive-Wegovy, other weight loss drugs ‘no silver bullet’, says WHO amid obesity review

New highly-effective weight loss drugs such as Novo Nordisk's Wegovy are not a “silver bullet” for addressing the rapid rise in global obesity rates, the World Health Organization’s nutrition chief told Reuters, as the agency conducts its first review of obesity management guidelines in more than 20 years.

Reuters

Read news from The Economist, FT, and more,
with one subscription

Novo Nordisk, A Top 1% Stock, Dives As Sales Of Obesity Blockbuster Drug Miss

Novo Nordisk stock slumped Thursday after its weight loss blockbuster, Wegovy, missed sales expectations despite rocketing demand.

Investors Business Daily

What's behind shortages of Adderall, Ozempic and other meds?

Drug shortages are growing in the United States, and experts see no clear path to resolving them

The Independent UK

Can drugs fix the UK’s adolescent obesity crisis?

A powerful new weight-loss medication may be approved for those aged 12 to 17. But healthcare professionals fear it ignores the underlying socioeconomic causes

The Guardian - UK

Children could be prescribed weight-loss jabs on the NHS

Department of Health asks watchdog to assess effectiveness of giving semaglutide to obese youngsters aged 12 to 17

The Guardian - UK

Viral Weight Loss Drugs Like Ozempic and Wegovy Sell For $10,000. Here's Why.

Viral demand for the shots producing dramatic weight loss has sent prices upward.

The Street

Doctors issue urgent warning over diabetes drug Ozempic being sold on Facebook Marketplace

The alert comes after an increased number of social media posts, in which users are marketing the drug as a rapid weight loss solution

Chronicle Live

Social Media adds to weight loss craze

GLP-1 agonists are a class of weight loss drug that is going viral on social media — but misinformation is rife

Salon

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

A ‘skinny jab’ is no quick fix for obesity – and no excuse to let junk food companies off the hook

Britain should be taxing unhealthy food and clamping down on marketing, says Sarah Boseley, the Guardian’s former health editor

Investors Business Daily

Novo Nordisk Sinks As Eli Lilly Plots Its Showdown In Obesity

Novo Nordisk stock dipped Monday after Eli Lilly posted the details of its study comparing Mounjaro and Wegovy in obesity treatment.

Tribune News Service

Social media is fueling enthusiasm for new weight loss drugs. Are regulators watching?

Suzette Zuena is her own best advertisement for weight loss.

Investors Business Daily

Novo Nordisk Surges To Another Record As Obesity Drugs Drive Higher Outlook

Novo Nordisk stock forged a new high Thursday after raising financial estimates, citing its diabetes and obesity treatments.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Red-Hot Obesity-Drug Maker Novo Nordisk Soars To Record On A $2.7 Billion Deal

Novo Nordisk stock popped Wednesday after the drugmaker inked a $2.7 billion deal that bolsters its diabetes and obesity treatments.

Chicago Sun-Times

Experts warn new weight loss medications carry long-term concerns

Some doctors, psychologists and eating disorder experts worry these new medications, originally developed to treat diabetes, could become a problem long-term.

Marie Claire

So, is Wegovy the same as Ozempic? Your need-to-knows about the controversial over-the-counter weight loss drugs

Two experts explain.

The Guardian - UK

Revealed: maker of Wegovy ‘skinny jab’ is funding NHS weight-loss services

Critics fear conflict of interest as Novo Nordisk helps medics ‘reduce unnecessary barriers’ to treatment for obesity

Reuters

EU backs use of Novo Nordisk's weight loss drug in adolescents

The European Medicines Agency said on Friday its committee has recommended expanding the use of Danish drugmaker Novo Nordisk's weight loss drug in adolescents aged 12 years and older.

Barchart

How Investors are Capitalizing on the Ozempic and Wegovy Craze

Ozempic and Wegovy started as injectable diabetes treatments. But now, these “appetite suppressants” are being touted as miracle weight loss drugs.

Investors Business Daily

Novo Hits Another Record High As WHO Considers A Key Move In Obesity

The World Health Organization will consider adding obesity treatments to its "essential medicines list." The move could help some drug stocks.

1 … 14 15 16 17

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations